---
schema_version: "secwatch.filing_event.v1"
accession: "0001581280-26-000012"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:09.481585+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance

## Summary
- Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.
- DNA Synthesis & Protein Solutions revenue $51.1M (+/- $0.1M), up 27% YoY.
- NGS Applications revenue $52.6M (+/- $0.1M), ahead of guidance; excluding one customer transition, NGS grew 18% YoY.
- Full Q1 financial results to be reported on Feb 2, 2026, before market open.

## SEC filing metadata
- accession: 0001581280-26-000012
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000012/0001581280-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000158128026000012/twist-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001581280-26-000012
- JSON: https://secwatch.observer/filing/0001581280-26-000012.json
- Plain text: https://secwatch.observer/filing/0001581280-26-000012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.